VASP Antibody

What is VASP and why is it important in cellular research?

VASP belongs to the Ena/VASP family of actin-associated proteins involved in cytoskeleton remodeling and cell polarity. It plays critical roles in various processes including axon guidance, lamellipodial and filopodial dynamics, platelet activation, and cell migration. VASP promotes actin filament elongation by protecting the barbed end of growing actin filaments against capping and increases the rate of actin polymerization in the presence of capping protein. Additionally, it stimulates actin filament elongation by facilitating the transfer of profilin-bound actin monomers onto growing filament ends. VASP also regulates actin dynamics in platelets and plays an important role in platelet aggregation, making it a significant target for investigation in multiple biological contexts .

What molecular weight should I expect when detecting VASP with antibodies?

When using VASP antibodies in Western blotting applications, you should expect to observe bands at approximately 46 and 50 kDa, which represent different phosphorylation states of the protein. While the calculated molecular weight of human VASP is approximately 39.8 kDa according to the sequence NP_003361.1, the observed molecular weight on gels is often higher due to post-translational modifications, particularly phosphorylation. This apparent molecular weight shift is consistent with earlier findings in literature. Similarly, for mouse VASP, though the calculated weight is 39.7 kDa (NP_033525.2), you may observe bands around 40 kDa in mouse tissue lysates .

What species cross-reactivity can I expect from commonly available VASP antibodies?

Commercially available VASP antibodies often demonstrate cross-reactivity across multiple mammalian species. For example, many VASP antibodies show reactivity with human, mouse, rat, and monkey samples. This cross-species reactivity is due to the high conservation of VASP protein sequence across mammalian species. When selecting a VASP antibody for your experiments, check the manufacturer's datasheet for specific species reactivity information. For instance, some antibodies have confirmed reactivity with human and mouse samples, while others may also react with rat and monkey samples .

What are the optimal applications for VASP antibodies in research?

VASP antibodies are versatile tools that can be employed in multiple experimental applications. Western blotting is the most common application, typically using dilutions around 1:1000. Additionally, these antibodies can be used effectively in immunohistochemistry with paraffin-embedded tissues (IHC-P), immunocytochemistry/immunofluorescence (ICC/IF), and enzyme-linked immunosorbent assays (ELISA). For phospho-specific VASP antibodies, such as those targeting phospho-S157 or phospho-S239, applications may include detecting changes in VASP phosphorylation status following various cellular stimuli or treatments. When designing experiments, consider that different antibodies may have optimized protocols for specific applications, so it's important to follow manufacturer recommendations for dilutions and sample preparation .

How should I optimize Western blotting protocols for VASP detection?

For optimal Western blotting results with VASP antibodies, consider the following methodological approach: Begin with sample preparation, where 0.2-0.5 μg of protein per well is typically sufficient for purified recombinant VASP, while 10-20 μg of total protein is recommended for cell or tissue lysates. Use a 10-12% polyacrylamide gel for optimal separation, as VASP (including its phosphorylated forms) has a molecular weight between 40-50 kDa. After transfer to a PVDF membrane, block with 5% BSA or skim milk in PBS or TBST for 1 hour at room temperature. Incubate with primary VASP antibody at the recommended dilution (typically 1:1000 to 1:3000) overnight at 4°C. For phospho-specific VASP antibodies, BSA is preferred over milk for blocking and antibody dilution. Following washing steps, incubate with an appropriate HRP-conjugated secondary antibody (typically at 1:5000-1:10000 dilution). Multiple washing steps with PBST or TBST are crucial between incubations. If signal strength is an issue, consider longer primary antibody incubation times or signal enhancement systems .

How can I effectively use phospho-specific VASP antibodies to study signaling pathways?

Phospho-specific VASP antibodies are powerful tools for studying signaling pathways, particularly those involving protein kinase A (PKA), protein kinase G (PKG), and protein kinase C (PKC). To effectively use these antibodies, treat your cells with pathway activators or inhibitors before harvesting. For instance, forskolin treatment (10-20 μM for 10-30 minutes) can be used to activate PKA and induce S157 phosphorylation. Similarly, NO donors or cGMP analogs can be used to study PKG-mediated phosphorylation at S239. After treatment, quickly lyse cells in phosphatase inhibitor-containing buffer to preserve phosphorylation status. When performing immunofluorescence, fix cells immediately after treatment using 4% paraformaldehyde for 15 minutes. For phospho-S157 VASP, look for enhanced staining at focal adhesions and plasma membrane after PKA activation, while phospho-S239 VASP may show distinct localization patterns. Always include both phospho-specific and total VASP antibodies in your analysis to calculate the ratio of phosphorylated to total protein, which provides a more accurate measure of pathway activation than absolute phosphorylation levels alone .

What are the key phosphorylation sites in VASP and how do they affect its function?

VASP has three major phosphorylation sites that significantly alter its function and localization: serine 157 (S157), serine 239 (S239), and threonine 278 (T278). Phosphorylation at S157, primarily mediated by PKA, results in a mobility shift from 46 to 50 kDa in SDS-PAGE and regulates VASP localization to focal adhesions and the plasma membrane. When S157 is phosphorylated, VASP shows enhanced accumulation at these sites and decreased association with stress fibers. Phosphorylation at S239, predominantly by PKG, does not cause a mobility shift but significantly affects VASP's actin polymerization activity by reducing its ability to promote filament elongation. T278 phosphorylation similarly affects actin polymerization properties. The combination of phosphorylation at different sites creates a complex regulatory system; for example, S157 phosphorylation alone has different functional consequences than combined phosphorylation at multiple sites. This differential phosphorylation pattern allows for precise spatial and temporal control of VASP function in response to various signaling pathways .

How does differential VASP phosphorylation affect its subcellular localization?

Differential phosphorylation of VASP dramatically alters its subcellular distribution, creating a dynamic spatial regulation system. In unstimulated cells, unphosphorylated VASP predominantly localizes to stress fibers with minor distribution to focal adhesions. Upon PKA activation and subsequent S157 phosphorylation, VASP redistributes from stress fibers to focal adhesions and the plasma membrane, particularly at lamellipodia-like structures. Research using phosphomimetic VASP mutants demonstrates that an acidic residue (mimicking phosphorylation) at position 157 significantly increases VASP accumulation at the leading edge of lamellipodia and at focal adhesion-like structures. Interestingly, the effect of phosphorylation status on subcellular localization can be cell-type specific. For instance, in endothelial cells (EC_VASP -/-), mutant localization was largely dependent on the phosphorylation status at position 157 but less affected by the phosphorylation status at the second and third sites. In contrast, in MV D7 cells, pseudophosphorylation at all three sites enhanced lamellipodia enrichment. This suggests that cell-type-specific factors interact with VASP's phosphorylation status to fine-tune its localization and subsequent function .

How can I distinguish between different phosphorylated forms of VASP in my experiments?

To effectively distinguish between different phosphorylated forms of VASP, a multi-faceted approach is recommended. First, use phospho-specific antibodies that selectively recognize VASP phosphorylated at specific sites (e.g., anti-phospho-S157-VASP or anti-phospho-S239-VASP). When performing Western blot analysis, phosphorylation at S157 causes a characteristic mobility shift from 46 to 50 kDa, providing a visual distinction between unphosphorylated and S157-phosphorylated VASP. This shift is not observed with S239 or T278 phosphorylation. For more precise quantification, consider using Phos-tag™ acrylamide gels, which can separate proteins based on their phosphorylation status regardless of mobility shifts. In immunofluorescence studies, counterstain with antibodies against total VASP and phospho-specific VASP to observe co-localization patterns. Differential subcellular localization can also serve as an indicator—S157-phosphorylated VASP predominantly localizes to focal adhesions and the plasma membrane, while the localization patterns of other phospho-forms may differ. Additionally, treating cells with specific kinase activators (forskolin for PKA, NO donors for PKG) or inhibitors can help validate the specificity of phospho-VASP signals by experimentally manipulating phosphorylation states .

What are common issues when using VASP antibodies and how can they be resolved?

Researchers frequently encounter several issues when working with VASP antibodies. One common problem is weak or absent signal in Western blotting, which can be addressed by increasing antibody concentration, extending incubation time (overnight at 4°C), or using enhanced chemiluminescence detection systems. For phospho-specific antibodies, rapid dephosphorylation during sample preparation may occur; prevent this by adding phosphatase inhibitors to lysis buffers and keeping samples cold throughout processing. Non-specific bands may appear due to antibody cross-reactivity; validate specificity using VASP knockout controls or peptide competition assays. When performing immunoprecipitation with VASP antibodies, optimizing the antibody-to-protein ratio is crucial—typically start with 1-2 μg of antibody per 100-500 μg of total protein. For immunofluorescence applications, high background can be reduced by extending blocking time, increasing washing steps, or using different blocking agents (5% BSA vs. normal serum). If detecting endogenous VASP is challenging, consider using signal amplification methods such as tyramide signal amplification for immunohistochemistry applications .

How should I validate the specificity of VASP antibodies in my experimental system?

Thorough validation of VASP antibody specificity is essential for generating reliable research data. Begin with Western blotting using positive controls like human platelets or other tissues known to express VASP at detectable levels. Include a negative control such as VASP knockout cells or tissues when available. For phospho-specific antibodies, compare samples treated with activators (forskolin for S157 phosphorylation) versus inhibitors of the relevant kinase pathway. Peptide competition assays provide another validation approach—pre-incubate the antibody with excess immunizing peptide before application to your samples; specific signals should be significantly reduced or eliminated. Immunoprecipitation followed by mass spectrometry can definitively confirm that the antibody is pulling down VASP rather than cross-reactive proteins. For immunostaining applications, compare the localization pattern with published VASP distribution data and use siRNA knockdown controls to confirm specificity. Cross-validate results using multiple antibodies targeting different epitopes of VASP when possible. Finally, remember that antibody performance can vary between applications—specificity in Western blotting doesn't guarantee specificity in immunohistochemistry .

What considerations are important when designing immunoprecipitation experiments with VASP antibodies?

When designing immunoprecipitation (IP) experiments with VASP antibodies, several methodological considerations can significantly improve results. Begin by optimizing your lysis buffer—a standard IP buffer containing PBS with 0.1% BSA and 0.1% Tween 20 works well for VASP, but additional detergents may be needed depending on VASP's subcellular localization in your specific cell type. The antibody-sample incubation step is critical; using 0.5 μg of purified VASP antibody with 50 μL of serum in 200 μL of IP buffer with overnight incubation at 4°C provides good results. For the immunoprecipitation step, 40 μL of 50% protein G sepharose with 2-hour incubation at 4°C on a shaker is typically sufficient. Thorough washing (3-5 times) with IP buffer is essential to reduce background. When eluting bound proteins, boiling in sodium dodecyl sulfate buffer for 5 minutes effectively disrupts antibody-antigen interactions. For co-immunoprecipitation studies investigating VASP-interacting proteins, consider using milder elution conditions to preserve protein-protein interactions. Cross-linking the antibody to beads may reduce antibody contamination in the eluate. For detecting phosphorylated VASP forms, include phosphatase inhibitors in all buffers. Finally, validate your IP results with reverse co-IP experiments when possible, and always include appropriate controls such as isotype antibodies or pre-immune serum .

How should I interpret changes in VASP phosphorylation patterns in response to experimental treatments?

Interpreting changes in VASP phosphorylation requires careful consideration of several factors. First, analyze both the degree and site-specificity of phosphorylation changes, as different sites have distinct functional implications. An increase in S157 phosphorylation (visible as a 46 to 50 kDa mobility shift) generally indicates PKA pathway activation and may correlate with changes in VASP localization to focal adhesions and the plasma membrane. Enhanced S239 phosphorylation (detectable only with phospho-specific antibodies) typically reflects PKG pathway activation and is associated with decreased actin polymerization activity. When analyzing Western blots, calculate the ratio of phosphorylated to total VASP rather than relying solely on phospho-signal intensity, as this controls for variations in total VASP expression or loading. For time-course experiments, note that different phosphorylation sites may have distinct kinetics of phosphorylation and dephosphorylation, which can provide insights into the temporal dynamics of signaling pathways. In immunofluorescence studies, carefully analyze changes in subcellular localization patterns, as these often correlate with specific phosphorylation states—for example, forskolin treatment (activating PKA) causes VASP redistribution from stress fibers to focal adhesions. Finally, remember that phosphorylation patterns may be cell-type specific, so findings in one cell type may not directly translate to others .

What are the implications of VASP phosphorylation for actin cytoskeleton dynamics?

VASP phosphorylation has profound implications for actin cytoskeleton dynamics, with different phosphorylation patterns precisely regulating VASP's ability to modulate actin filament assembly. When unphosphorylated, VASP efficiently promotes actin filament elongation by protecting barbed ends from capping proteins and facilitating the transfer of profilin-bound actin monomers to growing filaments. Phosphorylation at S239 (primarily by PKG) significantly impairs VASP's actin polymerization activity, leading to decreased filament elongation rates and potentially affecting cellular processes dependent on rapid actin assembly, such as lamellipodial protrusion. S157 phosphorylation (mainly by PKA) has more complex effects—while it doesn't directly inhibit actin polymerization activity, it dramatically alters VASP's subcellular localization, redistributing it from stress fibers to focal adhesions and the plasma membrane. This redistribution changes the spatial regulation of actin assembly within the cell, potentially enhancing actin polymerization at the leading edge while reducing it along stress fibers. Studies with phosphomimetic mutants demonstrate that the combinatorial effects of phosphorylation at multiple sites create a sophisticated regulatory system, allowing cells to fine-tune actin dynamics in response to various signals. For instance, cells expressing phosphomimetic VASP with negative charges at all three phosphorylation sites show dramatically different actin structures compared to cells expressing non-phosphorylatable VASP mutants .

How can I correlate VASP phosphorylation data with functional outcomes in my research model?

To meaningfully correlate VASP phosphorylation data with functional outcomes, employ a multi-parameter approach that connects molecular changes to cellular behaviors. Begin by establishing baseline VASP phosphorylation levels in your model system under standard conditions, then systematically manipulate relevant signaling pathways using pharmacological agents (e.g., forskolin for PKA activation) or genetic approaches (e.g., overexpression of constitutively active kinases). Quantify resulting changes in phosphorylation at specific sites (S157, S239, T278) using phospho-specific antibodies and Western blotting, ideally with normalization to total VASP levels. In parallel, assess functional outcomes relevant to VASP's known roles—measure parameters such as cell migration rates (wound healing assays), lamellipodia formation (live cell imaging), focal adhesion dynamics (using focal adhesion markers like vinculin), or actin polymerization rates (pyrene-actin assays with cell extracts). For more direct mechanistic insights, employ phosphomimetic or phospho-dead VASP mutants to model constitutive phosphorylation or dephosphorylation states. Statistical correlation analyses between phosphorylation levels and functional metrics can reveal significant relationships, though causation should be confirmed through rescue experiments. Remember that VASP functions within a complex network of actin-regulatory proteins, so changes in VASP phosphorylation may have context-dependent effects based on the expression and activity of other cytoskeletal regulators in your specific model system .

How can VASP antibodies be used to study neuropsychiatric disorders?

Recent research has identified anti-VASP antibodies as potential biomarkers for neuropsychiatric involvement in systemic lupus erythematosus (SLE), opening new avenues for studying neuropsychiatric disorders. To investigate this connection, researchers can employ a multi-faceted approach. First, develop or obtain ELISA protocols using purified recombinant human VASP (like Abcam item No. ab105601) to screen patient sera for anti-VASP autoantibodies. Use appropriate controls, including commercial anti-VASP antibodies as positive controls and PBS as negative controls. When analyzing patient cohorts, compare anti-VASP antibody levels between patients with and without neuropsychiatric symptoms, correlating antibody titers with specific symptom clusters or disease severity scores. To validate serum ELISA findings, perform immunoprecipitation experiments where patient serum is incubated with purified VASP, followed by protein G sepharose precipitation and Western blotting. For mechanistic studies, investigate how anti-VASP autoantibodies affect neuronal function by applying purified IgG from seropositive patients to neuronal cultures and assessing changes in morphology, electrophysiology, or calcium signaling. Complementary animal studies could involve passive transfer of human anti-VASP antibodies to mice, followed by behavioral and neuropathological assessments. This research direction connects cytoskeletal regulation to neuropsychiatric manifestations and may lead to new diagnostic tools and therapeutic targets .

What role does VASP play in infectious disease mechanisms, and how can antibodies help elucidate these processes?

VASP plays a crucial role in infectious disease mechanisms, particularly in bacterial pathogenesis where intracellular pathogens exploit host actin cytoskeleton machinery. Most notably, Listeria monocytogenes recruits and activates VASP to facilitate its actin-based motility within host cells, enabling cell-to-cell spread. To investigate these processes, researchers can use VASP antibodies in multiple experimental approaches. Immunofluorescence microscopy with phospho-specific and total VASP antibodies can reveal the recruitment and phosphorylation status of VASP at bacterial surfaces or actin comet tails. Time-lapse imaging combined with fluorescently tagged VASP constructs can demonstrate the dynamics of VASP recruitment during bacterial invasion and intracellular movement. For biochemical analyses, co-immunoprecipitation experiments using VASP antibodies can identify bacterial effector proteins that directly interact with VASP or modify its function. Phosphorylation-specific antibodies are particularly valuable for determining how bacterial infection affects host cell signaling pathways that regulate VASP activity. To establish causality, VASP knockout cells reconstituted with wild-type or phosphorylation-site mutants can be infected to assess how specific VASP functions impact bacterial entry, intracellular motility, and cell-to-cell spread. Similar approaches can be applied to study other pathogens that manipulate the actin cytoskeleton, such as Shigella, Rickettsia, and vaccinia virus, potentially revealing common mechanisms and unique pathogen-specific strategies .

How might VASP antibodies contribute to understanding platelet function in thrombotic disorders?

VASP antibodies offer powerful tools for investigating platelet function in thrombotic disorders due to VASP's critical role in regulating platelet activation and aggregation. Phosphorylation of VASP, particularly at S239 by PKG, serves as a key negative regulator of platelet activation in response to nitric oxide and prostacyclin signaling. To apply VASP antibodies in this context, researchers should first establish baseline phosphorylation profiles in resting platelets using phospho-specific antibodies against S157 and S239 sites. Flow cytometry with these antibodies can quantify VASP phosphorylation at the single-cell level, providing insights into platelet subpopulations with different activation states. For clinical applications, measure VASP phosphorylation in patient platelet samples before and after ex vivo stimulation with various agonists (ADP, thrombin, collagen) to assess signaling pathway integrity. The ratio of phosphorylated to total VASP after stimulation can serve as a biomarker for antiplatelet drug responsiveness—particularly for drugs targeting the P2Y12 receptor like clopidogrel. In thrombotic disorder research, compare VASP phosphorylation patterns between patients with different thrombotic conditions and healthy controls, correlating these molecular signatures with clinical outcomes. For mechanistic studies, combine VASP phosphorylation analysis with functional platelet assays such as aggregometry, adhesion under flow, and clot retraction. Such integrated approaches can reveal how alterations in VASP phosphorylation contribute to platelet hyperreactivity in conditions like diabetes, atherosclerosis, and inherited platelet disorders .

How are VASP antibodies being used to explore connections between cytoskeletal dynamics and cellular metabolism?

Emerging research is establishing important connections between cytoskeletal dynamics regulated by VASP and cellular metabolism. To investigate these connections, researchers are employing VASP antibodies in novel experimental paradigms. One approach involves examining how metabolic stress affects VASP phosphorylation patterns—cells can be subjected to glucose deprivation, hypoxia, or treatment with metabolic inhibitors, followed by Western blotting with phospho-specific VASP antibodies to detect changes in phosphorylation status. Immunofluorescence studies using these antibodies can reveal how metabolic perturbations alter VASP's subcellular localization and association with actin structures. Co-immunoprecipitation experiments with VASP antibodies, followed by mass spectrometry, can identify novel metabolic enzymes or regulators that physically interact with VASP under different metabolic conditions. For functional studies, researchers can correlate changes in VASP phosphorylation with alterations in glucose uptake, mitochondrial dynamics, or lipid metabolism. Particularly interesting is the potential role of VASP in mechanotransduction pathways that connect physical forces to metabolic responses—phospho-specific VASP antibodies can help determine how mechanical stimuli affect VASP phosphorylation and subsequent metabolic adaptation. This research direction has implications for understanding diseases with both cytoskeletal and metabolic components, such as cancer, where altered metabolism and abnormal cell migration often co-occur .